Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications
Peptide hormones of the glucagon-like peptide (GLP) family play an increasing clinical role, such as GLP-1 in diabetes therapy. Moreover, GLP receptors are over-expressed in various human tumor types and therefore represent molecular targets for important clinical applications. In particular, virtua...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2012-12-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fendo.2012.00158/full |
| _version_ | 1828381191212892160 |
|---|---|
| author | Meike eKörner Emanuel eChrist Damian eWild Jean Claude eReubi |
| author_facet | Meike eKörner Emanuel eChrist Damian eWild Jean Claude eReubi |
| author_sort | Meike eKörner |
| collection | DOAJ |
| description | Peptide hormones of the glucagon-like peptide (GLP) family play an increasing clinical role, such as GLP-1 in diabetes therapy. Moreover, GLP receptors are over-expressed in various human tumor types and therefore represent molecular targets for important clinical applications. In particular, virtually all benign insulinomas highly over-express GLP-1 receptors (GLP-1R). Targeting GLP-1R with the stable GLP-1 analogs 111In-DOTA/ DPTA-exendin-4 offers a new approach to successfully localize these small tumors. This non-invasive technique has the potential to replace the invasive localization of insulinomas by selective arterial stimulation and venous sampling. Malignant insulinomas, in contrast to their benign counterparts, express GLP-1R in only one third of the cases, while they more often express the somatostatin type 2 receptors. Importantly, one of the two receptors appears to be always expressed in malignant insulinomas. The GLP-1R overexpression in selected cancers is worth to be kept in mind with regard to the increasing use of GLP-1 analogs for diabetes therapy. While the functional role of GLP-1R in neoplasia is not known yet, it may be safe to monitore patients undergoing GLP-1 therapy carefully. |
| first_indexed | 2024-12-10T04:11:13Z |
| format | Article |
| id | doaj.art-18abe4f965fb4feba84c90f6491ae830 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-12-10T04:11:13Z |
| publishDate | 2012-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-18abe4f965fb4feba84c90f6491ae8302022-12-22T02:02:44ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922012-12-01310.3389/fendo.2012.0015835115Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applicationsMeike eKörner0Emanuel eChrist1Damian eWild2Jean Claude eReubi3Institute of Pathology, University of BerneUniversity Hospital BerneUniversitätsspital BaselInstitute of Pathology, University of BernePeptide hormones of the glucagon-like peptide (GLP) family play an increasing clinical role, such as GLP-1 in diabetes therapy. Moreover, GLP receptors are over-expressed in various human tumor types and therefore represent molecular targets for important clinical applications. In particular, virtually all benign insulinomas highly over-express GLP-1 receptors (GLP-1R). Targeting GLP-1R with the stable GLP-1 analogs 111In-DOTA/ DPTA-exendin-4 offers a new approach to successfully localize these small tumors. This non-invasive technique has the potential to replace the invasive localization of insulinomas by selective arterial stimulation and venous sampling. Malignant insulinomas, in contrast to their benign counterparts, express GLP-1R in only one third of the cases, while they more often express the somatostatin type 2 receptors. Importantly, one of the two receptors appears to be always expressed in malignant insulinomas. The GLP-1R overexpression in selected cancers is worth to be kept in mind with regard to the increasing use of GLP-1 analogs for diabetes therapy. While the functional role of GLP-1R in neoplasia is not known yet, it may be safe to monitore patients undergoing GLP-1 therapy carefully.http://journal.frontiersin.org/Journal/10.3389/fendo.2012.00158/fullInsulinomasomatostatin receptorsGlucagon-like peptide-1Glucagon-like petide-1 receptor111In-DOTA/DPTA-exendin-4. |
| spellingShingle | Meike eKörner Emanuel eChrist Damian eWild Jean Claude eReubi Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications Frontiers in Endocrinology Insulinoma somatostatin receptors Glucagon-like peptide-1 Glucagon-like petide-1 receptor 111In-DOTA/DPTA-exendin-4. |
| title | Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications |
| title_full | Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications |
| title_fullStr | Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications |
| title_full_unstemmed | Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications |
| title_short | Glucagon-like peptide-1 receptor overexpression in cancer and its impact on clinical applications |
| title_sort | glucagon like peptide 1 receptor overexpression in cancer and its impact on clinical applications |
| topic | Insulinoma somatostatin receptors Glucagon-like peptide-1 Glucagon-like petide-1 receptor 111In-DOTA/DPTA-exendin-4. |
| url | http://journal.frontiersin.org/Journal/10.3389/fendo.2012.00158/full |
| work_keys_str_mv | AT meikeekorner glucagonlikepeptide1receptoroverexpressionincanceranditsimpactonclinicalapplications AT emanuelechrist glucagonlikepeptide1receptoroverexpressionincanceranditsimpactonclinicalapplications AT damianewild glucagonlikepeptide1receptoroverexpressionincanceranditsimpactonclinicalapplications AT jeanclaudeereubi glucagonlikepeptide1receptoroverexpressionincanceranditsimpactonclinicalapplications |